(Q34579773)

3 August 2017

1 reference

title

Fas ligand and the fate of antitumour cytotoxic T lymphocytes (English)

1 reference

3 August 2017

0 references

Joe O'Connell

1

1 reference

3 August 2017

1 March 2002

1 reference

3 August 2017

1 reference

3 August 2017

105

1 reference

3 August 2017

3

1 reference

3 August 2017

263-266

1 reference

Fas and FasL in the homeostatic regulation of immune responses

3 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01379.X

Stimulation of CD95 (Fas) blocks T lymphocyte calcium channels through sphingomyelinase and sphingolipids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01379.X

Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01379.X

Inverse relation of Fas-ligand and tumor-infiltrating lymphocytes in angiosarcoma: indications of apoptotic tumor counterattack.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01379.X

Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01379.X

Regulation of the proinflammatory effects of Fas ligand (CD95L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2567.2002.01379.X

Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782665

Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782665

Expression of Fas(APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782665

The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782665

Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1782665

Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer

27 October 2018

1 reference

12 December 2020

Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis

1 reference

12 December 2020

Immune privilege or inflammation? Insights into the Fas ligand enigma

1 reference

12 December 2020

Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis

1 reference

12 December 2020

Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells

1 reference

12 December 2020

Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand

1 reference

12 December 2020

Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects

1 reference

12 December 2020

10.1046/J.1365-2567.2002.01379.X

Identifiers

DOI

1 reference

3 August 2017

0 references

1 reference

PubMed ID

11918687